<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841763</url>
  </required_header>
  <id_info>
    <org_study_id>V87P13</org_study_id>
    <secondary_id>2008-003871-32</secondary_id>
    <nct_id>NCT00841763</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects</brief_title>
  <official_title>A Phase III, Randomized, Controlled, Observer-blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted With MF59 (Fluad-H5N1) in Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present study, phase III, randomized, controlled, observer-blind, multicenter study, will
      evaluate safety, tolerability and immunogenicity of two doses of an adjuvanted monovalent
      influenza vaccine compared with an adjuvanted interpandemic trivalent influenza vaccine in a
      population of healthy adult and elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic Influenza Vaccine</measure>
    <time_frame>Up to 7 days after each vaccination</time_frame>
    <description>To assess the safety and tolerability profile of two doses of the MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) pandemic influenza vaccine (MF59-eH5N1), each containing 7.5 μg of H5N1 antigen in terms of the number of participants who reported local and systemic reactions up to 7 days after each vaccination per vaccination group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine as Compared With the Adjuvanted Seasonal Trivalent Influenza Vaccine</measure>
    <time_frame>Up to 7 days after each vaccination</time_frame>
    <description>To evaluate the safety and tolerability profile of two dose of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1) as compared with the MF59-adjuvanted seasonal trivalent influenza vaccine (MF59-eTIV), in terms of the number of participants who reported local and systemic reactions up to 7 days after each vaccination per vaccination group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain</measure>
    <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
    <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen,in terms of Geometric Mean Titers(GMTs) against the homologous A/Vietnam/1194/2004 strain, as determined by hemagglutination Inhibition(HI) assay and Microneutralization(MN) assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Areas After Two Doses of the Adjuvanted Monovalent Influenza Virus Vaccine (aH5N1)</measure>
    <time_frame>3 weeks after vaccination (day22, day 43, day 64)</time_frame>
    <description>To evaluate the immunogenicity of two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1), in terms of Geometric Mean Areas (GMAs) as determined by Single Radial Haemolysis(SRH) assay.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain</measure>
    <time_frame>3 weeks after vaccination (day 43/day22, day 64/day43)</time_frame>
    <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen,in terms of Geometric Mean Ratio(GMRs) against the homologous A/Vietnam/1194/2004 strain, as determined by HI, MN and SRH assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Participants Achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas ≥ 25mm2, After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain)</measure>
    <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
    <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the homologous A/Vietnam/1194/2004 strain, in terms of percentage of subjects achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas (GMA) ≥ 25mm2, as determined by HI, MN and SRH assays.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Participants Achieving Seroconversion or Significant Increase in Antibody Titer After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain</measure>
    <time_frame>3 weeks after vaccination (day 43/day22 and day 64/day22)</time_frame>
    <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the homologous A/Vietnam/1194/2004 strain, in terms of percentage of subjects achieving significant increase or at least 4-Fold increase in antibody titer from baseline, as measured by HI, MN and SRH assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</measure>
    <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
    <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, in terms of Geometric Mean Titers (GMTs) against the heterologous A/turkey/Turkey/1/2005 strain, as determined by HI and MN assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Areas After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</measure>
    <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
    <description>To evaluate the immunogenicity of two doses of MF59-eH5N1, each containing 7.5µg of H5N1 antigen, in terms of Geometric Mean Areas (GMAs) against the heterologous A/turkey/Turkey/1/2005 strain, as determined by SRH assay.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</measure>
    <time_frame>3 weeks after vaccination (day 43/day 22 and day 64/day 22)</time_frame>
    <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 Vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, in terms of Geometric Mean Ratios (GMRs) against the heterologous A/turkey/Turkey/1/2005 strain, as determined by HI,MN and SRH assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Participants Achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas ≥ 25mm2, After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain</measure>
    <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
    <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the heterologous A/turkey/Turkey/1/2005 strain, in terms of percentage of subjects achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas (GMA) ≥ 25mm2 as determined by HI, MN and SRH assays.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Participants Achieving Seroconversion or Significant Increase in Antibody Titers, After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</measure>
    <time_frame>3 weeks after vaccination (day 43/day 22 and day 64/day 22)</time_frame>
    <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the heterologous A/turkey/Turkey/1/2005 strain, in terms of percentage of subjects achieving significant increase or at least 4-Fold increase in antibody titers from baseline as measured by HI, MN and SRH assays.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3647</enrollment>
  <condition>Pandemic Influenza Disease</condition>
  <arm_group>
    <arm_group_label>TIV + aH5N1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose of the non-adjuvanted trivalent influenza virus vaccine(TIV) followed by two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PL + aTIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First dose of placebo (PL-saline) followed by two doses of the adjuvanted trivalent influenza virus vaccine (aTIV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle.</description>
    <arm_group_label>PL + aTIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza virus vaccine (TIV)</intervention_name>
    <description>A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.</description>
    <arm_group_label>TIV + aH5N1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted monovalent influenza virus vaccine (aH5N1)</intervention_name>
    <description>Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.</description>
    <arm_group_label>TIV + aH5N1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted trivalent influenza vaccine (aTIV)</intervention_name>
    <description>Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.</description>
    <arm_group_label>PL + aTIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects 18 years of age and older who are mentally competent and who have signed an
             informed consent form after having received a detailed explanation of the study
             protocol;

          -  In good health as determined by:

               1. medical history,

               2. physical examination,

               3. clinical judgment of the Investigator;

          -  Able to understand and comply with all study procedures and to complete study diaries,
             can be contacted, and will be available for study visits;

        Exclusion Criteria:

          -  Receipt of another investigational agent within 4 weeks;

          -  Laboratory-confirmed influenza disease within 6 months prior to Visit 1;

          -  Receipt of influenza vaccination for current season 2008/2009;

          -  Experienced any acute disease or infection requiring systemic antibiotic or antiviral
             therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable)
             within the past 7 days;

          -  Experienced fever (defined as axillary temperature 38.0°C) within 7 days prior to
             Visit 1;

          -  Pregnant or breastfeeding;

          -  Females of childbearing potential who are sexually active and have not used or do not
             plan or refuse to use an acceptable method of birth control during the active phase of
             the study (at least up to three weeks after last vaccine injection);

          -  Any serious disease, such as: cancer, autoimmune disease (including rheumatoid
             arthritis); diabetes mellitus type I and type II; diabetes relating to genetic
             defects/syndromes, diseases of the exocrine pancreas or infections; advanced
             arteriosclerotic disease; severe chronic obstructive pulmonary disease (COPD), i.e.
             GOLD stages 3 and 4; acute or progressive hepatic disease and renal disease;
             congestive heart failure; Body Mass Index ≥35 kg/m2 where BMI reflects obesity and not
             high muscle mass;

          -  History of progressive or severe neurologic disorders, of any neurological symptoms or
             signs, or anaphylactic shock following administration of any study vaccine;

          -  Surgery planned during the study period;

          -  Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,
             neomycin or polymyxin or any other component of the study vaccines;

          -  Known or suspected impairment/alteration of immune function, for example, resulting
             from:

               1. receipt of immunosuppressive therapy (any corticosteroid therapy or cancer
                  chemotherapy) or other immunosuppressive agents within the past 60 days and for
                  the full length of the study;

               2. receipt of immunostimulants;

               3. receipt of parenteral immunoglobulin preparation, blood products and/or plasma
                  derivates within the past 3 months and for the full length of the study;

               4. suspected or known HIV infection or HIV-related disease;

          -  Receipt of non study vaccines (with the exception of post-exposure vaccination in a
             medical emergency, e.g. hepatitis, rabies, tetanus) within 3 weeks prior to Visit 1 or
             planned vaccination within 3 weeks following the last study vaccination;

          -  History of (or current) drug or alcohol abuse that in the investigator's opinion would
             interfere with safety of the subject or the evaluation of study objectives;

          -  Members of research staff and their relatives;

          -  Any condition, which, in the opinion of the Investigator, might interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic (15 sites)</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>12 Sites</name>
      <address>
        <city>München</city>
        <zip>80799</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine. 2012 Feb 8;30(7):1388-96. doi: 10.1016/j.vaccine.2011.12.009. Epub 2011 Dec 20.</citation>
    <PMID>22192847</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <results_first_submitted>July 4, 2011</results_first_submitted>
  <results_first_submitted_qc>December 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2013</results_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>virus</keyword>
  <keyword>pandemic influenza</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 27 centers across Finland and Germany</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TIV + aH5N1 (18 to 60 Yrs)</title>
          <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
        </group>
        <group group_id="P2">
          <title>PL+ aTIV (18 to 60 Yrs)</title>
          <description>First dose of placebo (PL) followed by two doses of influenza virus vaccine (aTIV)</description>
        </group>
        <group group_id="P3">
          <title>TIV + aH5N1 (&gt;60 Yrs)</title>
          <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
        </group>
        <group group_id="P4">
          <title>PL + aTIV (&gt;60 Yrs)</title>
          <description>First dose of placebo (PL) followed by two doses of influenza virus vaccine (aTIV)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2691"/>
                <participants group_id="P2" count="681"/>
                <participants group_id="P3" count="219"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2529"/>
                <participants group_id="P2" count="624"/>
                <participants group_id="P3" count="211"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reasons</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to Classify</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TIV + aH5N1</title>
          <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1).</description>
        </group>
        <group group_id="B2">
          <title>PL+ aTIV</title>
          <description>First dose of placebo (PL) followed by two doses of influenza virus vaccine (aTIV)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2911"/>
            <count group_id="B2" value="735"/>
            <count group_id="B3" value="3646"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>The number of subjects analyzed is not consistent with the Participant Flow module due to randomization errors. The enrolled set as randomized is reported in the Participant Flow Module but in the Baseline Measure module, the enrolled set as treated is reported (2 randomization errors so 2 subjects were changed from the TIV+aH5N1 group to the PL+aTIV group). Moreover, a subset to the enrolled population as treated excluded the one subject who was not vaccinated.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>&lt;= 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.7" spread="11.6"/>
                    <measurement group_id="B2" value="40.5" spread="12.0"/>
                    <measurement group_id="B3" value="40.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;60 years (N=196, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="1.4"/>
                    <measurement group_id="B2" value="62.1" spread="1.8"/>
                    <measurement group_id="B3" value="61.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female (&lt;=60 yrs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1502"/>
                    <measurement group_id="B2" value="388"/>
                    <measurement group_id="B3" value="1890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male(&lt;=60 yrs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1190"/>
                    <measurement group_id="B2" value="291"/>
                    <measurement group_id="B3" value="1481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female (&gt;60 yrs; N= 109; 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male(&gt;60 yrs; N= 110, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic Influenza Vaccine</title>
        <description>To assess the safety and tolerability profile of two doses of the MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) pandemic influenza vaccine (MF59-eH5N1), each containing 7.5 μg of H5N1 antigen in terms of the number of participants who reported local and systemic reactions up to 7 days after each vaccination per vaccination group.</description>
        <time_frame>Up to 7 days after each vaccination</time_frame>
        <population>The analysis was performed on the Safety Set population</population>
        <group_list>
          <group group_id="O1">
            <title>TIV + aH5N1 (18-60 Yrs)</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O2">
            <title>TIV + aH5N1 (&gt;60 Yrs)</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic Influenza Vaccine</title>
          <description>To assess the safety and tolerability profile of two doses of the MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) pandemic influenza vaccine (MF59-eH5N1), each containing 7.5 μg of H5N1 antigen in terms of the number of participants who reported local and systemic reactions up to 7 days after each vaccination per vaccination group.</description>
          <population>The analysis was performed on the Safety Set population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2611"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1755"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="652"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="549"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1537"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1387"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="869"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="638"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38C (N=2610,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home (N=2591,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic Antipyretic medication used (N=2608,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine as Compared With the Adjuvanted Seasonal Trivalent Influenza Vaccine</title>
        <description>To evaluate the safety and tolerability profile of two dose of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1) as compared with the MF59-adjuvanted seasonal trivalent influenza vaccine (MF59-eTIV), in terms of the number of participants who reported local and systemic reactions up to 7 days after each vaccination per vaccination group.</description>
        <time_frame>Up to 7 days after each vaccination</time_frame>
        <population>The analysis was performed on the Safety set population</population>
        <group_list>
          <group group_id="O1">
            <title>TIV + aH5N1 (18-60 Yrs)</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O2">
            <title>PL+ aTIV (18-60 Yrs)</title>
            <description>First dose of placebo (PL) followed by two doses of influenza virus vaccine (aTIV)</description>
          </group>
          <group group_id="O3">
            <title>TIV + aH5N1 (&gt;60 Yrs)</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O4">
            <title>PL + aTIV (&gt;60 Yrs)</title>
            <description>First dose of placebo (PL) followed by two doses of influenza virus vaccine (aTIV)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine as Compared With the Adjuvanted Seasonal Trivalent Influenza Vaccine</title>
          <description>To evaluate the safety and tolerability profile of two dose of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1) as compared with the MF59-adjuvanted seasonal trivalent influenza vaccine (MF59-eTIV), in terms of the number of participants who reported local and systemic reactions up to 7 days after each vaccination per vaccination group.</description>
          <population>The analysis was performed on the Safety set population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2611"/>
                <count group_id="O2" value="658"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1755"/>
                    <measurement group_id="O2" value="502"/>
                    <measurement group_id="O3" value="115"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="652"/>
                    <measurement group_id="O2" value="206"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="549"/>
                    <measurement group_id="O2" value="181"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409"/>
                    <measurement group_id="O2" value="162"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1537"/>
                    <measurement group_id="O2" value="448"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1387"/>
                    <measurement group_id="O2" value="386"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="869"/>
                    <measurement group_id="O2" value="277"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="638"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38C (N=2610,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home (N=2591,651,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AnalgesicAntipyreticMedica used(N=2608,658,214,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain</title>
        <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen,in terms of Geometric Mean Titers(GMTs) against the homologous A/Vietnam/1194/2004 strain, as determined by hemagglutination Inhibition(HI) assay and Microneutralization(MN) assay.</description>
        <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
        <population>The analysis was performed on the Full Analysis Set (FAS) of the Immunogenicity Subset.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV + aH5N1 (18-60 Yrs) HI Assay</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O2">
            <title>TIV + aH5N1 (&gt;60 Yrs) HI Assay</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O3">
            <title>TIV + aH5N1 (18-60 Yrs) MN Assay</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O4">
            <title>TIV + aH5N1 (&gt;60 Yrs) MN Assay</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain</title>
          <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen,in terms of Geometric Mean Titers(GMTs) against the homologous A/Vietnam/1194/2004 strain, as determined by hemagglutination Inhibition(HI) assay and Microneutralization(MN) assay.</description>
          <population>The analysis was performed on the Full Analysis Set (FAS) of the Immunogenicity Subset.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" lower_limit="5.58" upper_limit="6.83"/>
                    <measurement group_id="O2" value="6.98" lower_limit="6.21" upper_limit="7.85"/>
                    <measurement group_id="O3" value="11" lower_limit="10" upper_limit="11"/>
                    <measurement group_id="O4" value="10" lower_limit="9.97" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=196,201,197,207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="17"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="18"/>
                    <measurement group_id="O3" value="17" lower_limit="15" upper_limit="19"/>
                    <measurement group_id="O4" value="17" lower_limit="15" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 (N=195,203,197,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="34" upper_limit="56"/>
                    <measurement group_id="O2" value="36" lower_limit="28" upper_limit="45"/>
                    <measurement group_id="O3" value="65" lower_limit="56" upper_limit="77"/>
                    <measurement group_id="O4" value="45" lower_limit="39" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Areas After Two Doses of the Adjuvanted Monovalent Influenza Virus Vaccine (aH5N1)</title>
        <description>To evaluate the immunogenicity of two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1), in terms of Geometric Mean Areas (GMAs) as determined by Single Radial Haemolysis(SRH) assay.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
        <time_frame>3 weeks after vaccination (day22, day 43, day 64)</time_frame>
        <population>The analysis was performed on the Full Analysis Set (FAS) of the Immunogenicity Subset.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV + aH5N1 (18-60 Yrs)</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O2">
            <title>TIV + aH5N1 (&gt;60 Yrs)</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Areas After Two Doses of the Adjuvanted Monovalent Influenza Virus Vaccine (aH5N1)</title>
          <description>To evaluate the immunogenicity of two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1), in terms of Geometric Mean Areas (GMAs) as determined by Single Radial Haemolysis(SRH) assay.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
          <population>The analysis was performed on the Full Analysis Set (FAS) of the Immunogenicity Subset.</population>
          <units>Areas (mm^2)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.45" upper_limit="12"/>
                    <measurement group_id="O2" value="13" lower_limit="11" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=197,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="18" upper_limit="24"/>
                    <measurement group_id="O2" value="20" lower_limit="18" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 (N=197,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="39" upper_limit="47"/>
                    <measurement group_id="O2" value="37" lower_limit="33" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain</title>
        <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen,in terms of Geometric Mean Ratio(GMRs) against the homologous A/Vietnam/1194/2004 strain, as determined by HI, MN and SRH assays.</description>
        <time_frame>3 weeks after vaccination (day 43/day22, day 64/day43)</time_frame>
        <population>The analysis was performed on the Full Analysis Set (FAS) of the Immunogenicity Subset.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV + aH5N1 (18-60 Yrs) HI Assay</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O2">
            <title>TIV + aH5N1 (&gt;60 Yrs) HI Assay</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O3">
            <title>TIV + aH5N1 (18-60 Yrs) MN Assay</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O4">
            <title>TIV + aH5N1 (&gt;60 Yrs) MN Assay</title>
            <description>First dose of trivalent influenza vaccine (TIV) followed by two doses of adjuvanted monovalent influenza virus vaccine (aH5N1)</description>
          </group>
          <group group_id="O5">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) SRH Assay</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O6">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) SRH Assay</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain</title>
          <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen,in terms of Geometric Mean Ratio(GMRs) against the homologous A/Vietnam/1194/2004 strain, as determined by HI, MN and SRH assays.</description>
          <population>The analysis was performed on the Full Analysis Set (FAS) of the Immunogenicity Subset.</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="209"/>
                <count group_id="O5" value="197"/>
                <count group_id="O6" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 43 to Day 22 (N=196,201,197,207,197,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.86" upper_limit="2.72"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.8" upper_limit="2.54"/>
                    <measurement group_id="O3" value="1.58" lower_limit="1.39" upper_limit="1.79"/>
                    <measurement group_id="O4" value="1.63" lower_limit="1.43" upper_limit="1.84"/>
                    <measurement group_id="O5" value="1.95" lower_limit="1.72" upper_limit="2.2"/>
                    <measurement group_id="O6" value="1.57" lower_limit="1.41" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 to Day 43 (N=195,203,197,208,197,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="5.52" upper_limit="9.14"/>
                    <measurement group_id="O2" value="5.15" lower_limit="4.15" upper_limit="6.4"/>
                    <measurement group_id="O3" value="6.21" lower_limit="5.29" upper_limit="7.29"/>
                    <measurement group_id="O4" value="4.42" lower_limit="3.79" upper_limit="5.15"/>
                    <measurement group_id="O5" value="4.03" lower_limit="3.54" upper_limit="4.59"/>
                    <measurement group_id="O6" value="2.9" lower_limit="2.53" upper_limit="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Participants Achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas ≥ 25mm2, After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain)</title>
        <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the homologous A/Vietnam/1194/2004 strain, in terms of percentage of subjects achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas (GMA) ≥ 25mm2, as determined by HI, MN and SRH assays.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
        <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
        <population>The analysis was performed on the Full Analysis Set (FAS) of the Immunogenicity Subset.</population>
        <group_list>
          <group group_id="O1">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) HI Titers≥40</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) HI Titers≥ 40</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O3">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) MN Titers≥40</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O4">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) MN Titers ≥40</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O5">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) SRH Areas ≥ 25mm2</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O6">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) SRH Areas ≥25mm2</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants Achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas ≥ 25mm2, After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain)</title>
          <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the homologous A/Vietnam/1194/2004 strain, in terms of percentage of subjects achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas (GMA) ≥ 25mm2, as determined by HI, MN and SRH assays.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
          <population>The analysis was performed on the Full Analysis Set (FAS) of the Immunogenicity Subset.</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="209"/>
                <count group_id="O5" value="197"/>
                <count group_id="O6" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="12"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O5" value="19" lower_limit="14" upper_limit="26"/>
                    <measurement group_id="O6" value="25" lower_limit="20" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=196,201,197,207,197,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="23" upper_limit="37"/>
                    <measurement group_id="O2" value="31" lower_limit="25" upper_limit="38"/>
                    <measurement group_id="O3" value="16" lower_limit="11" upper_limit="22"/>
                    <measurement group_id="O4" value="19" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O5" value="48" lower_limit="41" upper_limit="55"/>
                    <measurement group_id="O6" value="46" lower_limit="39" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 (N=195,203,197,208,197,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="53" upper_limit="67"/>
                    <measurement group_id="O2" value="57" lower_limit="50" upper_limit="64"/>
                    <measurement group_id="O3" value="67" lower_limit="60" upper_limit="74"/>
                    <measurement group_id="O4" value="57" lower_limit="50" upper_limit="64"/>
                    <measurement group_id="O5" value="91" lower_limit="87" upper_limit="95"/>
                    <measurement group_id="O6" value="82" lower_limit="76" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Participants Achieving Seroconversion or Significant Increase in Antibody Titer After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain</title>
        <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the homologous A/Vietnam/1194/2004 strain, in terms of percentage of subjects achieving significant increase or at least 4-Fold increase in antibody titer from baseline, as measured by HI, MN and SRH assays.</description>
        <time_frame>3 weeks after vaccination (day 43/day22 and day 64/day22)</time_frame>
        <population>This analysis was performed on the Full Analysis Set population</population>
        <group_list>
          <group group_id="O1">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) HI Titers</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) HI Titers</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O3">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) MN Titers</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O4">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) MN Titers</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O5">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) SRH Areas</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O6">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) SRH Areas</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants Achieving Seroconversion or Significant Increase in Antibody Titer After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Homologous A/Vietnam/1194/2004 Strain</title>
          <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the homologous A/Vietnam/1194/2004 strain, in terms of percentage of subjects achieving significant increase or at least 4-Fold increase in antibody titer from baseline, as measured by HI, MN and SRH assays.</description>
          <population>This analysis was performed on the Full Analysis Set population</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="208"/>
                <count group_id="O5" value="197"/>
                <count group_id="O6" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 43 to Day 22 (N=196,201,197,207,197,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="18" upper_limit="30"/>
                    <measurement group_id="O2" value="22" lower_limit="16" upper_limit="28"/>
                    <measurement group_id="O3" value="14" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O4" value="18" lower_limit="13" upper_limit="24"/>
                    <measurement group_id="O5" value="37" lower_limit="30" upper_limit="44"/>
                    <measurement group_id="O6" value="23" lower_limit="17" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 to Day 22 (N=195,203,197,208,197,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="49" upper_limit="63"/>
                    <measurement group_id="O2" value="50" lower_limit="43" upper_limit="57"/>
                    <measurement group_id="O3" value="65" lower_limit="58" upper_limit="72"/>
                    <measurement group_id="O4" value="55" lower_limit="48" upper_limit="62"/>
                    <measurement group_id="O5" value="78" lower_limit="72" upper_limit="84"/>
                    <measurement group_id="O6" value="63" lower_limit="56" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</title>
        <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, in terms of Geometric Mean Titers (GMTs) against the heterologous A/turkey/Turkey/1/2005 strain, as determined by HI and MN assays.</description>
        <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
        <population>This analysis was performed on the Full Analysis set population.</population>
        <group_list>
          <group group_id="O1">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) HI Assay</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) HI Assay</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O3">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) MN Assay</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O4">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) MN Assay</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</title>
          <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, in terms of Geometric Mean Titers (GMTs) against the heterologous A/turkey/Turkey/1/2005 strain, as determined by HI and MN assays.</description>
          <population>This analysis was performed on the Full Analysis set population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.03" lower_limit="5.55" upper_limit="6.55"/>
                    <measurement group_id="O2" value="6.85" lower_limit="6.21" upper_limit="7.55"/>
                    <measurement group_id="O3" value="11" lower_limit="10" upper_limit="11"/>
                    <measurement group_id="O4" value="11" lower_limit="11" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=197,206,196,207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.03" lower_limit="7.07" upper_limit="9.12"/>
                    <measurement group_id="O2" value="8.87" lower_limit="7.69" upper_limit="10"/>
                    <measurement group_id="O3" value="15" lower_limit="13" upper_limit="17"/>
                    <measurement group_id="O4" value="15" lower_limit="13" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 (N=197,207,197,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="9.77" upper_limit="14"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="14"/>
                    <measurement group_id="O3" value="30" lower_limit="26" upper_limit="35"/>
                    <measurement group_id="O4" value="23" lower_limit="20" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Areas After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</title>
        <description>To evaluate the immunogenicity of two doses of MF59-eH5N1, each containing 7.5µg of H5N1 antigen, in terms of Geometric Mean Areas (GMAs) against the heterologous A/turkey/Turkey/1/2005 strain, as determined by SRH assay.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
        <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
        <population>This analysis was performed on the Full Analysis Set population.</population>
        <group_list>
          <group group_id="O1">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs)</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs)</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Areas After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</title>
          <description>To evaluate the immunogenicity of two doses of MF59-eH5N1, each containing 7.5µg of H5N1 antigen, in terms of Geometric Mean Areas (GMAs) against the heterologous A/turkey/Turkey/1/2005 strain, as determined by SRH assay.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
          <population>This analysis was performed on the Full Analysis Set population.</population>
          <units>Areas (mm^2)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.89" lower_limit="8.82" upper_limit="11"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=196,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="13" upper_limit="16"/>
                    <measurement group_id="O2" value="14" lower_limit="13" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 (N=197,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="O2" value="20" lower_limit="18" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</title>
        <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 Vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, in terms of Geometric Mean Ratios (GMRs) against the heterologous A/turkey/Turkey/1/2005 strain, as determined by HI,MN and SRH assays.</description>
        <time_frame>3 weeks after vaccination (day 43/day 22 and day 64/day 22)</time_frame>
        <population>This analysis was performed on the Full Analysis set population.</population>
        <group_list>
          <group group_id="O1">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) HI Assay</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) HI Assay</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O3">
            <title>eTIV_a + MF59-eH5N1 (18-60yrs) MN Assay</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O4">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) MN Assay</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O5">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) SRH Assay</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O6">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) SRH Assay</title>
            <description>First dose of the non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</title>
          <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 Vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, in terms of Geometric Mean Ratios (GMRs) against the heterologous A/turkey/Turkey/1/2005 strain, as determined by HI,MN and SRH assays.</description>
          <population>This analysis was performed on the Full Analysis set population.</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="210"/>
                <count group_id="O5" value="197"/>
                <count group_id="O6" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 43 to Day 22 (N=197,206,196,207,196,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.19" upper_limit="1.49"/>
                    <measurement group_id="O2" value="1.29" lower_limit="1.16" upper_limit="1.45"/>
                    <measurement group_id="O3" value="1.39" lower_limit="1.25" upper_limit="1.54"/>
                    <measurement group_id="O4" value="1.29" lower_limit="1.17" upper_limit="1.42"/>
                    <measurement group_id="O5" value="1.44" lower_limit="1.31" upper_limit="1.59"/>
                    <measurement group_id="O6" value="1.25" lower_limit="1.15" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 to Day 22 (N=197,207,197,208,197,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="1.64" upper_limit="2.25"/>
                    <measurement group_id="O2" value="1.79" lower_limit="1.56" upper_limit="2.06"/>
                    <measurement group_id="O3" value="2.77" lower_limit="2.4" upper_limit="3.2"/>
                    <measurement group_id="O4" value="2.01" lower_limit="1.78" upper_limit="2.26"/>
                    <measurement group_id="O5" value="2.37" lower_limit="2.1" upper_limit="2.67"/>
                    <measurement group_id="O6" value="1.74" lower_limit="1.57" upper_limit="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Participants Achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas ≥ 25mm2, After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain</title>
        <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the heterologous A/turkey/Turkey/1/2005 strain, in terms of percentage of subjects achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas (GMA) ≥ 25mm2 as determined by HI, MN and SRH assays.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
        <time_frame>3 weeks after vaccination (day 22, day 43, day 64)</time_frame>
        <population>This analysis was performed on the Full Analysis set population.</population>
        <group_list>
          <group group_id="O1">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) HI Titers ≥ 40</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) HI Titers ≥ 40</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O3">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) MN Titers≥ 40</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O4">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) MN Titers≥ 40</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O5">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) SRH Areas ≥ 25mm2</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O6">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) SRH Areas≥ 25mm2</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants Achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas ≥ 25mm2, After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain</title>
          <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the heterologous A/turkey/Turkey/1/2005 strain, in terms of percentage of subjects achieving Geometric Mean Titers ≥ 40 and Geometric Mean Areas (GMA) ≥ 25mm2 as determined by HI, MN and SRH assays.
GMA: For each vaccine group, least squares GMAs (for SRH data), associated 2-sided 95% confidence interval and median, minimal, and maximal titer value were determined for study day 22,43 and 64.</description>
          <population>This analysis was performed on the Full Analysis set population.</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="210"/>
                <count group_id="O5" value="197"/>
                <count group_id="O6" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O4" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O5" value="16" lower_limit="11" upper_limit="22"/>
                    <measurement group_id="O6" value="23" lower_limit="18" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=197,206,196 ,207 ,196,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="7" upper_limit="16"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O3" value="13" lower_limit="8" upper_limit="18"/>
                    <measurement group_id="O4" value="14" lower_limit="9" upper_limit="19"/>
                    <measurement group_id="O5" value="30" lower_limit="24" upper_limit="37"/>
                    <measurement group_id="O6" value="32" lower_limit="26" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 (N=197,207,197,208,197,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="18" upper_limit="30"/>
                    <measurement group_id="O2" value="25" lower_limit="19" upper_limit="32"/>
                    <measurement group_id="O3" value="39" lower_limit="32" upper_limit="46"/>
                    <measurement group_id="O4" value="30" lower_limit="24" upper_limit="37"/>
                    <measurement group_id="O5" value="59" lower_limit="52" upper_limit="66"/>
                    <measurement group_id="O6" value="48" lower_limit="41" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Participants Achieving Seroconversion or Significant Increase in Antibody Titers, After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</title>
        <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the heterologous A/turkey/Turkey/1/2005 strain, in terms of percentage of subjects achieving significant increase or at least 4-Fold increase in antibody titers from baseline as measured by HI, MN and SRH assays.</description>
        <time_frame>3 weeks after vaccination (day 43/day 22 and day 64/day 22)</time_frame>
        <population>This analysis was performed on the Full Analysis Set population.</population>
        <group_list>
          <group group_id="O1">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) HI Titers</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) HI Titers</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O3">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) MN Titers</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O4">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) MN Titers</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O5">
            <title>eTIV_a + MF59-eH5N1 (18-60 Yrs) SRH Areas</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
          <group group_id="O6">
            <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs) SRH Areas</title>
            <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine(eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants Achieving Seroconversion or Significant Increase in Antibody Titers, After Two Doses of the Adjuvanted Pandemic H5N1 Vaccine Against the Heterologous A/Turkey/Turkey/1/2005 Strain.</title>
          <description>To evaluate the immunogenicity of two doses of the adjuvanted pandemic H5N1 vaccine (MF59-eH5N1), each containing 7.5µg of H5N1 antigen, against the heterologous A/turkey/Turkey/1/2005 strain, in terms of percentage of subjects achieving significant increase or at least 4-Fold increase in antibody titers from baseline as measured by HI, MN and SRH assays.</description>
          <population>This analysis was performed on the Full Analysis Set population.</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="208"/>
                <count group_id="O5" value="197"/>
                <count group_id="O6" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 43 to Day 22 (N=197, 206,196,207,196,208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="13"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="12"/>
                    <measurement group_id="O3" value="9" lower_limit="5" upper_limit="14"/>
                    <measurement group_id="O4" value="9" lower_limit="6" upper_limit="14"/>
                    <measurement group_id="O5" value="18" lower_limit="13" upper_limit="24"/>
                    <measurement group_id="O6" value="10" lower_limit="6" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64 to Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O2" value="19" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O3" value="36" lower_limit="29" upper_limit="43"/>
                    <measurement group_id="O4" value="25" lower_limit="19" upper_limit="31"/>
                    <measurement group_id="O5" value="49" lower_limit="42" upper_limit="56"/>
                    <measurement group_id="O6" value="32" lower_limit="26" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day1 to Day 224</time_frame>
      <desc>The number of subjects in the module for Adverse Events (AEs) differs from the number of subjects in the Participant Flow module. This is because the analysis for the AEs module is based on the safety population whereas the Participant Flow module refers to the enrolled population.</desc>
      <group_list>
        <group group_id="E1">
          <title>eTIV_a + MF59-eH5N1 (18-60 Yrs)</title>
          <description>First dose of non-adjuvanted seasonal trivalent influenza vaccine (eTIV_a) followed by two doses of adjuvanted pandemic H5N1 vaccine (MF59-eH5N1)</description>
        </group>
        <group group_id="E2">
          <title>PL+MF59-eTIV (18-60yrs)</title>
          <description>First dose of placebo(PL) followed by two doses of adjuvanted seasonal trivalent influenza vaccine (MF59-eTIV)</description>
        </group>
        <group group_id="E3">
          <title>eTIV_a + MF59-eH5N1 (&gt;60 Yrs)</title>
          <description>First dose of non adjuvanted seasonal trivalent influenza vaccine (eTIV_a) followed by two doses of adjuvanted pandemic H5N1 influenza vaccine (MF59-eH5N1)</description>
        </group>
        <group group_id="E4">
          <title>PL+MF59-eTIV (&gt;60yrs)</title>
          <description>First dose of placebo (PL) followed by two doses of adjuvanted seasonal trivalent influenza vaccine (MF59-eTIV)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="2611"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="658"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibriliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Myocardial infraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Herpes zoster opthalmic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gas poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vaccination failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign hydatidiform mole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Cerebellar haemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Iminent abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Schizophrenia,paranoid type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral caruncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2611"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2276" subjects_at_risk="2611"/>
                <counts group_id="E2" subjects_affected="588" subjects_at_risk="658"/>
                <counts group_id="E3" subjects_affected="175" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="204" subjects_affected="204" subjects_at_risk="2611"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="658"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="345" subjects_affected="345" subjects_at_risk="2611"/>
                <counts group_id="E2" events="118" subjects_affected="118" subjects_at_risk="658"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="214"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="641" subjects_affected="641" subjects_at_risk="2611"/>
                <counts group_id="E2" events="186" subjects_affected="186" subjects_at_risk="658"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="214"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="645" subjects_affected="645" subjects_at_risk="2611"/>
                <counts group_id="E2" events="204" subjects_affected="204" subjects_at_risk="658"/>
                <counts group_id="E3" events="45" subjects_affected="45" subjects_at_risk="214"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Injection site haemorrahage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="234" subjects_affected="234" subjects_at_risk="2611"/>
                <counts group_id="E2" events="77" subjects_affected="77" subjects_at_risk="658"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="214"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="537" subjects_affected="537" subjects_at_risk="2611"/>
                <counts group_id="E2" events="178" subjects_affected="178" subjects_at_risk="658"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="214"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1516" subjects_affected="1516" subjects_at_risk="2611"/>
                <counts group_id="E2" events="442" subjects_affected="442" subjects_at_risk="658"/>
                <counts group_id="E3" events="87" subjects_affected="87" subjects_at_risk="214"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="405" subjects_affected="405" subjects_at_risk="2611"/>
                <counts group_id="E2" events="161" subjects_affected="161" subjects_at_risk="658"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="214"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="353" subjects_affected="353" subjects_at_risk="2611"/>
                <counts group_id="E2" events="128" subjects_affected="128" subjects_at_risk="658"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="214"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="222" subjects_affected="222" subjects_at_risk="2611"/>
                <counts group_id="E2" events="59" subjects_affected="59" subjects_at_risk="658"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="179" subjects_affected="179" subjects_at_risk="2611"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="658"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="214"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="84" subjects_affected="84" subjects_at_risk="2611"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="658"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="212" subjects_affected="212" subjects_at_risk="2611"/>
                <counts group_id="E2" events="82" subjects_affected="82" subjects_at_risk="658"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="214"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="863" subjects_affected="863" subjects_at_risk="2611"/>
                <counts group_id="E2" events="274" subjects_affected="274" subjects_at_risk="658"/>
                <counts group_id="E3" events="60" subjects_affected="60" subjects_at_risk="214"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="723" subjects_affected="723" subjects_at_risk="2611"/>
                <counts group_id="E2" events="194" subjects_affected="194" subjects_at_risk="658"/>
                <counts group_id="E3" events="44" subjects_affected="44" subjects_at_risk="214"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="57" subjects_affected="57" subjects_at_risk="2611"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="658"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="237" subjects_affected="237" subjects_at_risk="2611"/>
                <counts group_id="E2" events="62" subjects_affected="62" subjects_at_risk="658"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="2611"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="658"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

